Eric Stocker, MD
Cardiovascular Disease · San Antonio, TXNPI 1891765624
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,347 of the $229,452 with a category attached, or 79.5%. Amgen accounts for 62.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $75,541 and has fallen 87.6% since, to $9,360 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 520 payments — averaging $441.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$144K
- Esperion Therapeutics, Inc.$76K
- Althera Pharmaceuticals LLC$4K
- Novartis$3K
- Boston Scientific$1K
- Regeneron Healthcare Solutions, Inc.$352
- plus $1K from 14 others
What the payments were for
- Consulting fees$1,8001%
- Speaking & faculty fees$182,34779%
- Travel & lodging$35,63016%
- Food & beverage$9,6754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 259 | $143,866 |
| Esperion Therapeutics, Inc. | 143 | $75,830 |
| Althera Pharmaceuticals LLC | 9 | $4,048 |
| Novartis | 47 | $2,989 |
| Boston Scientific | 7 | $1,357 |
| Regeneron Healthcare Solutions, Inc. | 9 | $352 |
| Johnson & Johnson | 15 | $324 |
| Amarin Pharma, Inc. | 9 | $167 |
| AbbVie | 1 | $120 |
| Merck | 5 | $90 |
| Pfizer | 2 | $42 |
| Lilly USA, LLC | 2 | $39 |
| Agepha Pharma FZ LLC | 2 | $37 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| Cvrx, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,452 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $67,807 |
| Repatha SureclickEvolocumab | 59 | $61,006 |
| NexlizetBempedoic Acid/Ezetimibe | 48 | $28,226 |
| VascepaIcosapent Ethyl | 27 | $21,478 |
| Repatha PushtronexEvolocumab | 22 | $19,067 |
| XareltoRivaroxaban | 14 | $18,993 |
| FarxigaDapagliflozin Propanediol | 18 | $13,317 |
| Ezetimibe | 592 | $13,005 |
| BrilintaTicagrelor | 11 | $8,675 |
| Niacin ErNiacin | 61 | $5,848 |
| Rosuvastatin Calcium | 477 | $5,509 |
| Icosapent Ethyl | 11 | $3,768 |
| Metoprolol Succinate | 187 | $3,012 |
| Nebivolol Hcl | 28 | $2,234 |
| Atorvastatin Calcium | 197 | $1,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $67,80769 claims |
| Esperion Therapeutics, Inc.Nexlizet | $75,830 | $28,22648 claims |
| AstraZenecaFarxiga, Brilinta | $35 | $21,99229 claims |
| Johnson & JohnsonXarelto | $324 | $18,99314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in San Antonio
- Chandrasekhar KunavarapuSan Antonio$405K
- Mark ColliganSan Antonio$129K
- Manoj PandaySan Antonio$119K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.